Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 181.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,869 shares of the medical equipment provider’s stock after acquiring an additional 16,663 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zimmer Biomet were worth $2,793,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. M&G Plc acquired a new position in shares of Zimmer Biomet during the first quarter valued at $7,397,000. Gradient Investments LLC lifted its holdings in Zimmer Biomet by 17.3% in the second quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock worth $14,147,000 after purchasing an additional 19,224 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in Zimmer Biomet by 7.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after purchasing an additional 15,548 shares during the period. Swedbank AB acquired a new stake in Zimmer Biomet in the first quarter worth about $2,740,000. Finally, Border to Coast Pensions Partnership Ltd lifted its holdings in Zimmer Biomet by 4.5% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock worth $16,711,000 after purchasing an additional 6,623 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ZBH shares. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. UBS Group dropped their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Canaccord Genuity Group dropped their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Price Performance

Shares of ZBH opened at $109.53 on Tuesday. The company has a market capitalization of $21.80 billion, a price-to-earnings ratio of 20.71, a P/E/G ratio of 1.99 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The business’s 50-day moving average is $106.37 and its 200-day moving average is $110.33.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.65 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.